<DOC>
	<DOCNO>NCT01922739</DOCNO>
	<brief_summary>This 6-month , nonrandomized , open-label extension study ass long-term safety hydrocodone bitartrate extended-release tablet patient moderate severe chronic low back pain require continuous opioid treatment extend period time .</brief_summary>
	<brief_title>Open-Label , Extension Study Evaluate Safety Hydrocodone Bitartrate Extended-Release Tablets</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>1 . Patients must participate complete entire doubleblind treatment period study drug final study visit ( visit 12 ) study 3103 . NOTE : Patients final ontreatment visit ( visit 11.5 ) permit participate study 3104 . 2 . The patient able speak English willing provide write informed consent study 3104 , include resign write opioid agreement , participate study . 3 . Women childbearing potential ( surgically sterile 2 year postmenopausal ) must use medically accept method contraception , agree continue use method duration study 30 day participation study , negative pregnancy test screening . Acceptable method contraception include barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . NOTE : A woman consider surgically sterile tubal ligation , hysterectomy , bilateral salpingooophorectomy bilateral oophorectomy , hysterectomy bilateral salpingooophorectomy . 4 . The patient must willing able successfully selfadminister study drug , comply study restriction , return study center schedule study visit , specify protocol . 5 . The patient must participate study involve investigational agent ( exclude participate study 3103 ) enrol present study . 1 . The patient 's current source pain different low back pain patient experience entry study 3103 . NOTE : Any additional source pain patient must discuss medical monitor . 2 . The patient current evidence alcohol substance abuse exception nicotine caffeine . 3 . The patient develop , study 3103 , medical psychiatric disease ( include suicidality ) , opinion investigator , would compromise collect data . 4 . The patient expect surgery study . 5 . The patient pregnant lactating . 6 . The patient develop active malignancy ( exclude basal cell carcinoma ) study 3103 . 7 . The patient know human immunodeficiency virus ( HIV ) . 8 . In judgment investigator , patient clinically significant deviation normal physical examination and/or clinical laboratory test value . 9 . The patient develop cardiopulmonary disease would , opinion investigator , significantly increase risk treatment opioids . 10 . The patient receive monoamine oxidase inhibitor ( MAOI ) . Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>low back pain</keyword>
	<keyword>hydrocodone bitartrate</keyword>
	<keyword>opioids</keyword>
</DOC>